Drug Profile
YS HBV 001
Alternative Names: PIKA YS-HBV-001; YS-HBV-001Latest Information Update: 20 Mar 2023
Price :
$50
*
At a glance
- Originator Yisheng Biopharma
- Developer Yisheng Biopharma; YS Biopharma
- Class Hepatitis B vaccines
- Mechanism of Action Immunostimulants; Toll-like receptor 3 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Hepatitis B
Most Recent Events
- 20 Mar 2023 YS HBV 001 is still in phase I trials for Hepatitis B in Singapore
- 20 Mar 2023 YS Biopharma HBV 001 plans a phase II trial for Hepatitis B in 2023 (YS Biopharma pipeline, March 2023)
- 14 Mar 2023 Yisheng Biopharma has merged with Summit Healthcare Acquisition Corp. to form YS Biopharma